1. Home
  2. LITM vs NRXS Comparison

LITM vs NRXS Comparison

Compare LITM & NRXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

LITM

Snow Lake Resources Ltd.

HOLD

Current Price

$2.91

Market Cap

55.7M

ML Signal

HOLD

Logo Neuraxis Inc.

NRXS

Neuraxis Inc.

HOLD

Current Price

$5.34

Market Cap

46.3M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
LITM
NRXS
Founded
2018
2011
Country
Employees
N/A
N/A
Industry
Other Metals and Minerals
Sector
Basic Materials
Exchange
Nasdaq
Nasdaq
Market Cap
55.7M
46.3M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
LITM
NRXS
Price
$2.91
$5.34
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$8.00
AVG Volume (30 Days)
524.6K
83.5K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$31.05
Revenue Next Year
N/A
$146.31
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.34
$1.33
52 Week High
$10.38
$6.20

Technical Indicators

Market Signals
Indicator
LITM
NRXS
Relative Strength Index (RSI) 43.70 69.91
Support Level $2.91 $4.50
Resistance Level $3.12 $4.50
Average True Range (ATR) 0.30 0.38
MACD -0.01 0.04
Stochastic Oscillator 22.73 92.49

Price Performance

Historical Comparison
LITM
NRXS

About LITM Snow Lake Resources Ltd.

Snow Lake Resources Ltd is a Canadian nuclear fuel cycle and critical minerals company with a portfolio of U.S.-focused uranium projects, including the Pine Ridge Uranium Project in the Powder River Basin in Wyoming. The company also holds exploration-stage critical minerals projects including the Snow Lake Lithium Project, Shatford Lake Lithium Project, and Engo Valley Uranium Project in Manitoba, Canada, and Namibia. Snow Lake has investments in companies with critical minerals assets, including rare earths and lithium in North America. The primary commercial use for U3O8 is as fuel for nuclear power plants to generate electricity.

About NRXS Neuraxis Inc.

Neuraxis Inc is a growth stage company is engaged in developing neuromodulation therapies to address chronic and debilitating conditions in children. The company is dedicated to advancing the science with its' proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology. The company focuses on targeted therapies for the pediatric and adolescent population suffering from disorders of gut-brain interaction (DGBIs).

Share on Social Networks: